Tivic health partners with the feinstein institutes to advance its patent-pending, non-invasive cervical vagus nerve stimulation; begins optimization of ncvns for use in clinical indications

San francisco--(business wire)--tivic health® systems, inc. (“tivic health”, nasdaq: tivc), a health tech company that develops and commercializes bioelectronic medicine, announced today it has initiated the second phase of its clinical work to advance its novel non-invasive cervical vagus nerve stimulation (“ncvns”). the company has entered into a collaboration agreement with the feinstein institutes for medical research at northwell health to optimize its ncvns device therapy for use in speci.
TIVC Ratings Summary
TIVC Quant Ranking